Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
(1) REVISION AND RENEWAL OF EXISTING ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS UNDER THE EXCLUSIVE LICENCE AGREEMENTS; (2) REVISION AND RENEWAL OF EXISTING ANNUAL CAP FOR CONTINUING CONNECTED
Regulatory Filings Classification · 85% confidence The document is an official announcement made under Hong Kong Listing Rules describing the revision and renewal of annual caps for continuing connected transactions (related party framework agreements, licensing and supply agreements). It is regulatory in nature, covering connected transaction disclosures required under Chapter 14A of the Listing Rules. There is no indication that it is an earnings release, annual report, or any other specific category; it is a regulatory announcement. Therefore, the appropriate classification is the fallback category “Regulatory Filings” (Code: RNS).
2026-03-26 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025' and contains detailed financial tables, business highlights, and a 'Management Discussion and Analysis' section. While it is an announcement, it contains the full scope of the annual results and management commentary, which is characteristic of an Annual Results Announcement (often categorized as an Earnings Release or Annual Report depending on the jurisdiction's reporting requirements). Given the depth of the content (over 84,000 characters) and the inclusion of audited consolidated results, it functions as the primary disclosure of annual performance. FY 2025
2026-03-12 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1322 characters) from VISEN Pharmaceuticals stating that a board meeting will be held on 12 March 2026 to consider and approve the annual results for the year ended 31 December 2025. It does not contain the actual financial results, but rather announces the date of the meeting where these results will be discussed and approved for publication. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2026-03-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX for listed companies to report monthly movements in securities, share capital, and public float. It does not fit into specific categories like 'Share Issue' (as it is a recurring monthly report) or 'Annual Report'. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-03 English
INSIDE INFORMATION ANNOUNCEMENT BIOLOGICS LICENSE APPLICATION FOR LONAPEGSOMATROPIN FOR INJECTION APPROVED BY THE NMPA
Regulatory Filings Classification · 98% confidence The document is an 'Inside Information Announcement' issued by VISEN Pharmaceuticals regarding the NMPA approval of a Biologics License Application (BLA) for a specific drug. It is a regulatory disclosure required under the Hong Kong Stock Exchange Listing Rules. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory announcement of material information, it is classified as a Regulatory Filing (RNS).
2026-01-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in securities, share capital, and treasury shares. As it is a recurring regulatory filing mandated by the Exchange Listing Rules and does not fit into specific categories like 'Share Issue' (which would be a specific event) or 'Annual Report', it is best classified as a Regulatory Filing (RNS).
2026-01-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.